Trenbolone Acetate
High-potency short-ester trenbolone with rapid onset and controlled exposure windows.
Trenbolone Acetate
Trenbolone Acetate is a sterile oil-based injectable preparation of trenbolone esterified with acetic acid, presented at 100 milligrams per millilitre in a 10 mL multiple dose vial. Trenbolone is a 19-nortestosterone derivative distinguished by two additional double bonds in the steroid nucleus, a configuration that confers exceptionally high androgen receptor affinity.
Structural Profile
Trenbolone is 17-beta-hydroxyestra-4,9,11-trien-3-one. The 9,11-diene configuration prevents aromatisation entirely and blocks reduction by 5-alpha reductase. Esterified with acetic acid at the 17-beta position, the molecular formula is C20H24O3 with a molar mass of 312.40 g/mol, registered under CAS number 10161-34-9.
Esterification and Release
The acetate ester is the shortest in pharmaceutical use, a two-carbon chain that is mobilised from the intramuscular depot rapidly. Onset is swift and clearance equally so, which requires a short injection interval but permits close control over serum concentration.
Pharmacokinetic Profile
The elimination half-life is approximately 3 days. Serum concentrations rise within hours of administration and fall over the following days. The urinary detection window for trenbolone metabolites extends to approximately 5 months.
Mechanism of Action
Trenbolone binds the cytoplasmic androgen receptor with an affinity several times that of testosterone. The activated hormone-receptor complex engages androgen response elements and drives transcription of genes governing structural protein synthesis and nitrogen retention. Because the 4,9,11-triene structure is not a substrate for aromatase, no conversion to oestradiol occurs. Trenbolone additionally exhibits affinity for the glucocorticoid receptor, through which it opposes catabolic signalling in muscle tissue.
Manufacturing and Sterility
Each production lot is released against the complete pharmaceutical testing protocol: HPLC identity confirmation and purity analysis with a specification of not less than 98 percent, verification of concentration against label claim within 5 percent, sterility testing in accordance with USP <71>, bacterial endotoxin quantification by LAL assay below 0.25 EU/mL, and particulate matter inspection in accordance with USP <788>. A Certificate of Analysis is issued for every lot.
Quality Assurance
Every batch of Trenbolone Acetate produced by Biomedica undergoes the complete pharmaceutical release testing protocol before distribution. This includes HPLC compound identity confirmation and purity analysis (specification: ≥98%), concentration verification (specification: ±5% of label claim), sterility testing per USP <71>, bacterial endotoxin quantification by LAL assay (specification: <0.25 EU/mL), and particulate matter inspection per USP <788>. A Certificate of Analysis is issued for every production lot.
Authentication
Each unit of Trenbolone Acetate carries a unique authentication code on its outer packaging. This code can be verified instantly on our Authentication page to confirm the product is genuine Biomedica stock.